Last $66.45 USD
Change Today +2.87 / 4.51%
Volume 999.8K
LGND On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
OTC US
OTC US
As of 5:20 PM 03/3/15 All times are local (Market data is delayed by at least 15 minutes).

ligand pharmaceuticals (LGND) Snapshot

Open
$65.00
Previous Close
$63.58
Day High
$68.22
Day Low
$64.81
52 Week High
03/19/14 - $80.21
52 Week Low
10/9/14 - $41.99
Market Cap
1.3B
Average Volume 10 Days
368.8K
EPS TTM
$0.60
Shares Outstanding
19.6M
EX-Date
04/3/07
P/E TM
110.1x
Dividend
--
Dividend Yield
--
Current Stock Chart for LIGAND PHARMACEUTICALS (LGND)

ligand pharmaceuticals (LGND) Related Businessweek News

View More BusinessWeek News

ligand pharmaceuticals (LGND) Details

Ligand Pharmaceuticals Incorporated, a biotechnology company, acquires and develops royalty revenue generating assets in the United States. Its late-stage development programs include Promacta, an oral thrombopoietin receptor agonist therapy for the treatment of adult patients with chronic immune thrombocytopenic purpura; Kyprolis for the treatment of multiple myeloma; AVINZA, a pain therapeutic; Captisol-enabled Melphalan IV for the multiple myeloma transplant setting; Viviant (bazedoxifene) for the treatment of postmenopausal osteoporosis; and Nexterone, an injectable formulation. The company’s late-stage development programs that are in Phase III clinical trials comprise Captisol-enabled Noxafil-IV; MK-8931 Beta-Secretase Inhibitor program for the treatment of Alzheimer’s disease; Captisol-enabled Carbamazepine-IV for the management of acute seizure disorder for hospital or emergency settings; and Captisol-enabled Delafloxacin-IV for the treatment of acute bacterial skin and skin structure infections. It also offers Sparsentan that is in Phase II clinical trials for kidney diseases; Lasofoxifene, an estrogen partial agonist for osteoporosis treatment and other diseases; and Captisol-enabled Topiramate Injection, which is in Phase I clinical trials for the treatment of partial onset or primary generalized tonic-clonic seizures. In addition, the company’s preclinical stage products include HepDirect for liver diseases; Oral Human Granulocyte Colony Stimulating Factor for the treatment of Neutropenia; and IRAK4 Inhibitor for inflammation. Further, it provides Glucagon Receptor Antagonist that is in Phase I clinical trials for diabetes; Selective Androgen Receptor Modulator, which is in Phase II clinical trials for the therapeutic benefits; and Captisol-Enabled Clopidogrel that is in Phase III clinical trials for anti-coagulants. Ligand Pharmaceuticals Incorporated was founded in 1987 and is headquartered in La Jolla, California.

19 Employees
Last Reported Date: 02/23/15
Founded in 1987

ligand pharmaceuticals (LGND) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: $500.3K
President and Chief Operating Officer
Total Annual Compensation: $368.1K
Chief Financial Officer and Vice President of...
Total Annual Compensation: $294.6K
Vice President, General Counsel and Secretary
Total Annual Compensation: $283.4K
Compensation as of Fiscal Year 2013.

ligand pharmaceuticals (LGND) Key Developments

Ligand Pharmaceuticals Incorporated Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Earnings Guidance for the First Quarter and Full Year of 2015

Ligand Pharmaceuticals Incorporated reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. Total revenues for the fourth quarter of 2014 were $23.0 million, an increase of 56% compared with $14.7 million for the same period in 2013. Net income was $7.1 million, or $0.34 per diluted share, compared with net income for the fourth quarter of 2013 of $1.9 million, or $0.09 per diluted share. Non-GAAP net income from continuing operations for the fourth quarter of 2014 was $12.5 million, or $0.60 per diluted share, compared with non-GAAP net income from continuing operations for the fourth quarter of 2013 of $7.5 million, or $0.35 per diluted share. Total revenues for 2014 increased 32% to $64.5 million compared with $49.0 million for 2013. Net income from continuing operations for 2014 was $12.0 million, or $0.56 per diluted share, compared with net income from continuing operations of $8.8 million, or $0.43 per share, for 2013. Non-GAAP net income from continuing operations for 2014 was $32.6 million, or $1.52 per diluted share, compared with $19.0 million, or $0.92 per diluted share, for 2013. Net income was $12.02 million, or $0.56 per diluted share, compared with net income of $11.42 million, or $0.43 per diluted share. For the first quarter of 2015, the company expects total revenues to be between $13.0 million and $13.5 million and non-GAAP earnings per diluted share to be between $0.25 and $0.27. The non-GAAP earnings per diluted share guidance does not include changes in contingent liabilities, mark-to-market adjustment for amounts owed to licensors, non-cash stock based compensation expense and non-cash debt related costs. Affirming its previous full-year 2015 financial forecast, the company expects total revenues to be between $81.0 million and $83.0 million, and non-GAAP earnings per diluted share to be between $2.14 and $2.18. The company expects that approximately half of 2015 revenue will be derived from royalties.

Ligand Signs License Agreement with Sermonix for Lasofoxifene

Ligand Pharmaceuticals Incorporated announced the signing of a license agreement with Sermonix Pharmaceuticals LLC for the development and commercialization of oral lasofoxifene in the United States and additional territories. Under the terms of the agreement, Ligand has received an undisclosed initial payment, and is entitled to receive up to $45 million in potential regulatory and commercial milestone payments and tiered royalties of 6% to 10% on future net sales.

Ligand Pharmaceuticals Incorporated Announces Management Changes

Ligand Pharmaceuticals Incorporated announced that Matthew W. Foehr has been promoted to President and Chief Operating Officer. Previously Mr. Foehr served as the company's Executive Vice President and Chief Operating Officer. John Higgins, who had been serving as President and Chief Executive Officer, will continue to serve as the company's Chief Executive Officer. Mr. Foehr has more than 20 years of experience in the pharmaceutical industry, having managed global operations and various research and development programs. Prior to joining Ligand in 2011, he was Vice President and Head of Consumer Dermatology R&D, as well as Acting Chief Scientific Officer of Dermatology, in the Stiefel division of GlaxoSmithKline (GSK).

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LGND:US $66.45 USD +2.87

LGND Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for LGND.
View Industry Companies
 

Industry Analysis

LGND

Industry Average

Valuation LGND Industry Range
Price/Earnings 98.2x
Price/Sales 17.0x
Price/Book 41.0x
Price/Cash Flow 89.7x
TEV/Sales 11.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LIGAND PHARMACEUTICALS, please visit www.ligand.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.